SAEs, or AEs leading to study drug discontinuation were not seen in any of the arms, whether MTX was added or not.
Background:
The primary goal of current therapeutic strategies in RA is to control disease activity and at the same time to prevent radiographic progression. A disconnect between a missing radiographic progression and higher disease activity under treatment with biologic agents has been discussed. In general, analyses of radiographic progression in RA rather focus on radiographic nonprogression or repair and high radiographic progression in spite of therapy has, to our knowledge not been analysed in detail in the last years, neither in RCTs nor in cohort studies. Objectives: To analyse the occurrence of high radiographic destruction and it's development in the era of biologic treatment.
Methods:
We included all RA patients from the Swiss registry SCQM with at least two subsequently scored radiographs. Radiographic destruction was scored with the Ratingen erosion score and calculated by dividing the change of Ratingen scores by time (>6 months) between two subsequent radiographs. To analyse high radiographic progression we looked for the height and time of the highest (peak) radiographic progression in every individual patient for the analysis. The individual peak radiographic progression was analysed in groups as change of Ratingen scores/year: 0-≤10, 10-≤20, 20-≤30, >30 (groups 1-4). The time point of the individual peak radiographic progression was analysed per group (follow up 1998 -2015) . The baseline disease characteristics were compared using standard descriptive statistics (Kruskal-Wallis or Chi-square tests). Results: 4'033 patients were included into the analysis. 3'049 patients had a peak radiographic progression between 0 and ≤10/year, 773 between 10 and ≤20, 150 between 20 and ≤30, and 61 of >30. All patient groups were within the same age range (mean: 56.5 -60.5 years). Rheumatoid factor and ACPA were more frequent in patient groups with higher peak radiographic progression (RF: 73.6, 80.0, 88.9, 90.0; ACPA: 66.8, 73.4, 74.3, 82.1, respectively) . When the rate of radiographic progression before and after peak progression was analysed, 69.7%, 74.7%, 76.9%, and 93.3% of the patients had a radiographic progression of 25% or lower as compared to peak progression before and 76.1%, 81.8%, 91.1%, and 93.8% after this peak progression, respectively for patients in groups 1 to 4 ( Figure A) . The disease activity, as assessed by DAS 28, was significantly higher in all patient groups before peak progression and lower thereafter (Figure B, p<0.001) . Average HAQ-DI scores increased after peak radiographic progression in group 4 (Figure C, p=0.005) whereas it is stable or even decreases among the patients of the other patient groups.
Conclusions:
High peak radiographic progression is a rear phenomenon that gets less frequent in patients over the last years of observation. This may be an effect of modern therapy. Among the patients with high radiographic progression, (1) a greater delay between diagnosis and first symptoms was found and (2) the use of biologic agents was less frequent. These data suggest that the decreasing frequency of very high radiographic peak progression in the Swiss RA patients reflect a more effective therapeutic approach in the last years. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.4232 SAT0060 RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS selected for outcome analyses. Among seropositive patients, both LDA and remission were less frequently achieved in case of RF-positivity. Relevantly, in ACPA-positive patients (n=273), the co-occurrence of RF dose-dependently influenced clinical outcomes. After 6 months of treatment, LDA and disease remission were achieved respectively by 69.6% and 47.8% of single ACPApositive, 68.8% and 37.5% of ACPA-positive RF-low, and 57% and 27.6% of ACPA-positive RF-high patients (chi-square for trend p=0.18 for LDA, p=0.05 for remission). After adjusting for confounders (age, gender, symptoms' duration, baseline disease activity, use of prednisone, recruitment period), high levels of RF independently predicted failure to achieve LDA with an HR (95% CI) of 0.61 (0.39 to 0.95) and failure to achieve remission with an HR (95% CI) of 0.63 (0.35 to 0.99) (Figure 1 ). In contrast, ACPA levels did not show any significant predictive value, neither for thresholds of >3 ULN nor of >100 U.
Conclusions: Among ACPA-positive RA patients, disease characteristics may vary in association with the extent of overall humoral autoimmunity. In particular, the concomitant presence of high levels of IgM RF seems associated with lower response rates to csDMARDs. Collectively, these findings highlight the importance of further subclassifying patients with autoantibody-positive RA in order get deeper insights into disease mechanisms and clinical outcomes. Objectives: We compared remission rates, according to different definitions of remission in rheumatoid arthritis (RA) and investigated the potential predictors of sustained remission at the 2-year follow-up. Methods: We obtained data on 291 RA outpatients, seen from July 2009 to September 2012. Sociodemographic data and answers to questionnaires were collected in face-to-face interviews. Remission was defined according to the Disease Activity Score in 28 joints (DAS28)-ESR, DAS28-CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), and ACR/EULAR Boolean definition. Sustained remission was defined as when the patient continued in remission at two consecutive annual assessments. Predictors of sustained remission according to the DAS28-CRP were assessed by univariate and multivariate analyses. Results: For the 291 RA patients, the remission rates of RA were 17.9% (DAS28-ESR), 54.3% (DAS28-CRP), 10.3% (SDAI), 10.0% (CDAI), and 5.8% (Boolean). On follow-up for 2 years, the sustained remission rates of RA were 46.5% (DAS28), 55.0% (DAS28-CRP), 37.5% (SDAI), 32.0% (CDAI), and 30.8% (Boolean). RA patients who achieve sustained remission according to the DAS28-CRP were younger, and had more education, higher monthly income, lower Health Assessment Questionnaire (HAQ) score, lower physician global assessment, lower patient global assessment, lower patient pain assessment, and higher EQ-5D. In multivariate analysis, only the HAQ score predicted sustained remission according to DAS28-CRP (OR=0.257, 95% CI 0.067-0.980, p =0.047). Conclusions: The remission rates of RA patients differed according to the definition of remission, and the highest sustained remission rate was classified by the DAS28-CRP. A lower HAQ score was an independent predictor of sustained remission over 2 years, according to the DAS28-CRP. Background: The HONOR (humira discontinuation without functional and radiographic damage following sustained remission) study was designed to investigate the possibility of patients discontinuing adalimumab (ADA) therapy for 1 year without flaring (DAS28-ESR ≥3.2). 14-3-3η is a mechanistic serum marker that is modifiable over the disease course, does not correlate with CRP and is a predictor of radiographic progression even in patients who achieve clinical remission. The uncoupling of inflammation and joint damage processes in RA underscores a risk of premature discontinuation of biologic treatment when aiming to achieve sustained remission. Serum markers that could indicate which patients are at risk of flare and continued joint damage despite clinical remission are highly desirable. Objectives: In this study, serum 14-3-3η was investigated as a predictor of joint damage and flares in the HONOR cohort. Methods: Serum 14-3-3η levels were measured in 62 Japanese patients, 51 of which were from the HONOR study at baseline, 1-year after treatment initiation, at discontinuation and at the time of flare. Of the 62 patients, 46 (74%) patients achieved sustained drug-free remission up to 1 year following ADA discontinuation. Sharp van der Heidje (SHS) scores were available at therapy initiation, discontinuation, and at 52 weeks following. Relationships between continuous variables were assessed using uni-and multi-variable Gaussian linear regression models and logistic regression. Results: At baseline and discontinuation, median (QR) 14-3-3η levels were 0.28 ng/ml (0.07-2.11) and 0.22 ng/ml (0.04-1.28) respectively, with 26 (59%) of 44 and 29 (54%) of 54 patients being positive (≥0.19 ng/ml) at the corresponding time-points. Paired t-test revealed that levels of 14-3-3η were significantly different between baseline and discontinuation, p=0.030. Level of 14-3-3η at baseline was positively associated with SHS at 12 months and at the time of flare, p=0.038. Bivariable modeling revealed that baseline 14-3-3η together with the change in 14-3-3η had a significant interacting effect on SHS at 12 months and the time of flare, p=0.02. Higher baseline 14-3-3η levels together with an increase in levels at the time of discontinuation was strongly associated with an increased SHS. Adding CRP, flare, sustained remission through 12 months, MTX dose at initiation and at ADA discontinuation did not improve predictive effects of 14-3-3η with SHS. Baseline 14-3-3η levels alone was not associated with flares at 12 months (p=0.15) however when combined with CRP, a significant interaction was present (p=0.03). Specifically, patients with a low CRP, and a high 14-3-3η level had a higher likelihood of flaring versus those with a low 14-3-3η, 22% versus 12%. Conclusions: Baseline 14-3-3η and increases in its levels are associated with worse radiographic outcomes in patients who achieve clinical remission and discontinue ADA. To reduce the risk of flare in patients who are candidates for discontinuation of ADA, CRP and 14-3-3η measurements should be considered in combination as markers of flare prediction. Background: Treat-to-target (T2T) approach suggests using a composite index when following patients with rheumatoid arthritis (RA) without identifying which one to use. Objectives: In this prospective study we aimed to compare the accuracy of different indices for RA patients in remission taking Ultrasound Global Synovitis Score (GLOESS) as a gold standard and their predictive value for flares in 2 years. Methods: RA patients who were considered to be in clinical remission according to the clinician were recruited. Disease activity was assessed using DAS28-CRP, CDAI, SDAI and RAPID-3 and 38 joints per patient were scanned by US and scored according to GLOESS. The total GLOESS scores were calculated for 38 joints and also for 28 joints by excluding the MTP joints. The number of joints with ≥2 GLOESS was calculated. Flare data was collected in 3 subsequent visits in the following 2 years, whenever available. Results: Ninety-six consecutive patients (80.2% females) were recruited. Patients were more frequently categorized as being in remission using DAS28 (80%) compared to CDAI (50%), SDAI (45.2%) and RAPID 3 (37.5%). Patients that were in remission according to CDAI had lower GLOESS scores on 28 joints (p=0.05) and had less joints with ≥2 signals (p=0.04) ( 
